Cellectar Biosciences presents data on PLE molecules in tumors
Cellectar Biosciences announced Jarrod Longcor, chief business officer of Cellectar, presented a poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology, being held from October 15 - 17, 2019 in London, United Kingdom. The poster, entitled: "Phospholipid ether delivery vehicle shows specificity for a broad range of tumor cells and provides a novel and improved approach for targeted therapy," featured data demonstrating that phospholipid ether drug conjugates were capable of delivering small molecule cytotoxins selectively to tumor cells and were well tolerated in animal models. In the data presented, all animals exposed to a single infusion of the payload alone died, while all animals receiving multiple doses with the PDCs survived with no adverse effects observed at all dose levels tested. Additionally, PDCs showed rapid uptake and release of 20% to 40% of the conjugate and payload in a wide range of tumor cells. The PDCs also demonstrated potent activity against the tumor cells with inhibitory concentrations in the low nanomolar range.